Participating Companies

4SC AG [VSC:DB] €30 MM MCap
An epi­ge­net­ic fo­cused com­pany de­vel­op­ing small molecule drugs for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany’s lead com­pound, Res­mi­no­s­tat, is fo­cused on Cu­ta­neous T Cell Lym­pho­ma but has un­part­nered as­sets for Hod­kins Lym­pho­na, Col­orec­tal Can­cer, and HCC. [more in­for­ma­tion]
Achilles Therapeutics [ACHL] $41 MM MCap
cNeT (clo­n­al neoanti­gen) pro­cess builds on TILs, com­bined with abil­i­ty to iden­ti­fy pt-spe­cif­ic clo­n­al neoanti­gens and gen­er­ate per­so­n­al­ized T-cell ther­a­pies. Sep19 GBP100 mil­lion Se­ries B w/ RA, Syn­co­na, For­bion, In­vus, Per­cep­tive + Red­mile. [more in­for­ma­tion]
Anavex Life Sciences Corp. [AVXL] $758 MM MCap
The lead com­pound ANAVEX2-73 re­ceived or­phan drug desig­na­tion from the FDA in Rett Syn­drome, with Ph 2 trial ini­ti­at­ing 1H2018. 2-73 is a small-molecule ac­ti­va­tor of the sig­ma-1 re­cep­tor which has shown ca­pa­ble of res­tor­ing neu­ral cell home­os­ta­sis. The anal­y­sis of RNA and whole ex­ome DNA genome se­quenc­ing da­ta has char­ac­ter­ized sev­er­al ge­nom­ic al­ter­a­tions in well-char­ac­ter­ized tar­gets that can be used as bio­mark­ers to iden­ti­fy op­ti­mal pa­tients in forth­com­ing clin­i­cal trials (Rett, Alzheimer’s, and Parkin­son’s). [more in­for­ma­tion]
Apeiron Investment Group LLC
Ape­iron fo­cus­es on Fi­nan­cial Ser­vices (es­pe­cial­ly fin­tech and cryp­to as­sets), Tech­nol­o­gy, Life Sci­ences, Me­dia & En­ter­tain­ment and Re­al Es­tate & Prop-Tech. As of 2022 cir­ca US$ 3.5bn AUM. They in­vest in all phas­es and stages of a com­pany’s life cy­cle, but fo­cus on non-list­ed Seed/Start-up in­vest­ments and larg­er size Re­struc­tur­ing & Spe­cial Si­t­u­a­tions deals (of­ten list­ed). [more in­for­ma­tion]
Bain Capital Life Sciences
Bain Cap­i­tal Life Sci­ences in­vests in bio­phar­ma­ceu­ti­cal, spe­cial­ty phar­ma­ceu­ti­cal, med­i­cal de­vice, di­ag­nos­tics and en­abling life sci­ence tech­nol­o­gy com­pa­nies glob­al­ly, with a fo­cus on com­pa­nies that both drive med­i­cal in­no­va­tion across the val­ue chain and en­able that in­no­va­tion to im­prove the lives of pa­tients with un­met med­i­cal needs. The dif­fer­en­ti­at­ed skillset of Bain Cap­i­tal’s team en­ables it to pur­sue op­por­tu­ni­ties cre­at­ed by sev­er­al longterm trends in health­care. In par­tic­u­lar, th­ese trends are cre­at­ing an in­creased need for tar­get­ed cap­i­tal and val­ue-add­ed strate­g­ic sup­port of com­pa­nies around their crit­i­cal phas­es of growth, dur­ing which they must prove their clin­i­cal and busi­ness val­ue. [more in­for­ma­tion]
BioNTech AG [BNTX] $26,261 MM MCap
BioN­Tech AG is a ful­ly in­te­grat­ed biotech com­pany which com­bines all build­ing blocks of im­munother­a­pies un­der one roof. Through its di­ver­si­fied tech­nol­o­gy plat­forms and in-house di­ag­nos­tics and man­u­fac­tur­ing units, BioN­Tech is strate­g­i­cal­ly po­si­tioned to im­ple­ment its lab-bench-to-mar­ket strat­e­gy. BioN­Tech is pi­oneer­ing dis­rup­tive tech­nolo­gies rang­ing from in­di­vi­d­u­al­ized mR­NA based medicines through in­no­va­tive Chimer­ic Anti­gen Re­cep­tors and T-cell Re­cep­tor-based prod­ucts and nov­el anti­body check­point im­muno­mo­d­u­la­tors. [more in­for­ma­tion]
BlueStar Investment Managers SA (Onelife Advisors)
BlueS­tar is an as­set ma­n­age­ment com­pany head­quar­tered in Lugano, Switz­er­land, spe­cial­is­ing in ma­n­ag­ing in­vest­ment funds and ad­vis­ing in­sti­tu­tio­n­al clients on as­set al­lo­ca­tion, the­mat­ic in­vest­ments and in­vest­ment so­lu­tions. [more in­for­ma­tion]
Calliditas Therapeutics [CALT] $499 MM MCap
Cal­lid­i­tas’ com­mon shares are list­ed on Nas­daq Stock­holm (tick­er: CALTX) and its Amer­i­can De­posi­tary Shares are list­ed on the Nas­daq Glob­al Se­lect Mar­ket (tick­er: CALT). [more in­for­ma­tion]
Our clients range from pre-rev­enue pri­vate start-up com­pa­nies to For­tune 100 public com­pa­nies, in­clud­ing vari­ous pri­vate equi­ty firms and their port­fo­lio com­pa­nies in all in­dus­tries. We work with fi­nance lead­ers dur­ing ev­ery stage of the busi­ness life­cy­cle to solve com­plex busi­ness chal­lenges. In the life sci­ences in­dus­try, CF­GI has been a trust­ed part­n­er to com­pa­nies from IPO pre­pa­ra­tion, ad­vis­ing on tech­ni­cal ac­count­ing mat­ters, de­vel­op­ment of in­ter­nal con­trols com­pliance pro­grams, in­ter­im SEC re­port­ing sup­port, and val­u­a­tion of IPR&D. [more in­for­ma­tion]
Crescendo Biologics
Cres­cen­do Bi­o­log­ics is a clin­i­cal stage com­pany de­vel­op­ing T cell en­hanc­ing ther­a­peu­tics. Cres­cen­do’s lead pro­gramme, CB307, is a CD137 (4-1BB) x PS­MA bis­pe­cif­ic. CB307’s unique for­mat de­liv­ers tu­mour-spe­cif­ic killing, while avoid­ing sys­temic toxic­i­ty, and can be ap­plied to a broad range of PS­MA-pos­i­tive can­cer in­di­ca­tions. It is de­signed to cause the pro­lif­er­a­tion of tu­mour-spe­cif­ic T cells, cre­at­ing a safe, broad, longer-last­ing an­ti-tu­mour re­sponse and will be in the clin­ic in ear­ly 2021. [more in­for­ma­tion]
CureVac [CVAC] $1,930 MM MCap
In Ju­ly 2020, Cure­Vac en­tered in a col­lab­o­ra­tion with GSK to joint­ly de­vel­op new prod­ucts in pro­phy­lac­tic vaccines for in­fec­tious dis­eas­es based on Cure­Vac’s se­cond-gen­er­a­tion mR­NA tech­nol­o­gy. This col­lab­o­ra­tion was lat­er ex­tend­ed to the de­vel­op­ment of se­cond-gen­er­a­tion COVID-19 vaccine can­di­dates, and mod­i­fied mR­NA vaccine tech­nolo­gies. Based on its pro­pri­e­tary tech­nol­o­gy, Cure­Vac has built a deep clin­i­cal pipe­line across the ar­eas of pro­phy­lac­tic vaccines, can­cer ther­a­pies, anti­body ther­a­pies, and the treat­ment of rare dis­eas­es. [more in­for­ma­tion]
Ernst & Young
Ernst & Young Limit­ed is a glob­al lead­er in as­su­r­ance, tax, tran­s­ac­tion and ad­vi­so­ry ser­vices. [more in­for­ma­tion]
Ethris has de­vel­oped a com­plete suite of nov­el, pro­pri­e­tary and best-in-class mR­NA-mod­i­fi­ca­tion, LNP for­mu­la­ton, de­liv­ery and man­u­fac­tur­ing plat­forms to pro­vide high­ly ver­satile, mul­ti-route, mul­ti-car­go de­liv­ery op­tions for in­tra­mus­cu­lar, in­haled or nasal ad­min­is­tra­tion. Ethris' rich pipe­line com­pris­es 6+ pro­grams with 3 near-term clin­i­cal en­tries. [more in­for­ma­tion]
Glycostem Therapeutics
Gly­costem Ther­a­peu­tics is a Dutch biotech com­pany. Gly­costem Ther­a­peu­tics is the trade name of the le­gal en­ti­ty IPD Ther­a­peu­tics BV, which has been estab­lished in De­cem­ber 2007. Gly­costem Ther­a­peu­tics has de­vel­oped the world's first GMP com­pliant NK-cell plat­form that is ready for in­dus­trial scale-up. [more in­for­ma­tion]
Goodwin Procter LLP
More than 1,000 cor­po­rate and liti­ga­tion at­tor­neys lev­er­age their spe­cif­ic ex­pe­ri­ence and as­sem­ble full-ser­vice teams to ad­vise clients in th­ese and ad­ja­cent in­dus­tries. [more in­for­ma­tion]
H.C. Wainwright & Co., LLC
is a full-ser­vice in­vest­ment bank that of­fers equi­ty re­search ser­vices to in­sti­tu­tio­n­al and re­tail in­ves­tors. The firm of­fers cor­po­rate fi­nance, pri­vate client, as­set ma­n­age­ment and in­sti­tu­tio­n­al sales/trad­ing ser­vices. H.C. [more in­for­ma­tion]
Heights Capital Management, Inc.
Heights Cap­i­tal Ma­n­age­ment, Inc. is a San Fran­cis­co based pri­vate equi­ty firm spe­cial­iz­ing in pri­vate in­vest­ments in public equi­ty in emerg­ing growth com­pa­nies. [more in­for­ma­tion]
Immatics NV [IMTX] $827 MM MCap
Im­mat­ics com­bines the dis­cov­ery of true tar­gets for can­cer im­munother­a­pies with the de­vel­op­ment of the right T cell re­cep­tors with the goal of en­abling a ro­bust and spe­cif­ic T cell re­sponse against th­ese tar­gets. This deep know-how is the foun­da­tion for our pipe­line of Adop­tive Cell Ther­a­pies and TCR Bis­pe­cifics as well as our part­n­er­ships with glob­al lead­ers in the phar­ma­ceu­ti­cal in­dus­try. We are com­mitt­ed to de­liv­er­ing the pow­er of T cells and to un­lock­ing new av­enues for pa­tients in their fight against can­cer. [more in­for­ma­tion]
InflaRx N.V. [IFRX] $184 MM MCap
Fol­low-on molecule, IFX-2, in pre-clin­i­cal de­vel­op­ment for ad­di­tio­n­al sub-acute, chron­ic in­flam­ma­to­ry in­di­ca­tions. [more in­for­ma­tion]
[more in­for­ma­tion]
iOnc­tu­ra’s drug de­vel­op­ment pro­grams com­bine im­mune-me­di­at­ed and di­rect an­ti-tu­mor ac­tiv­i­ty to de­liv­er molecules with su­pe­ri­or clin­i­cal ef­fi­ca­cy and safe­ty in on­col­o­gy. Its lead pro­gram, IOA-244, has de­liv­ered com­pelling clin­i­cal monother­a­py ef­fi­ca­cy and safe­ty da­ta in solid and he­ma­to­log­ic ma­lig­nan­cies and has syn­er­gis­tic po­ten­tial with stan­dard of care agents across tu­mor types. iOnc­tu­ra’s se­cond clin­i­cal pro­gram, IOA-289, is ini­ti­at­ing dos­ing in a Phase 1b in first-line pan­cre­at­ic can­cer in 3Q22. [more in­for­ma­tion]
Cre­at­ing the new gen­er­a­tion of bi­o­log­ics us­ing its plant-based plat­form that has de­mon­s­trat­ed an abil­i­ty to cre­ate po­ten­tial­ly bet­ter drug can­di­dates at a frac­tion of the time and cost of con­ven­tio­n­al plat­forms. Fo­cused on dis­cov­er­ing mon­o­clo­n­al anti­bodies tar­get­ing vali­dat­ed path­ways for rare and in­fec­tious dis­eas­es and, due to the speed and ac­cu­ra­cy of its anti­body pro­duc­tion sys­tem, is po­si­tioned well to de­vel­op fast fol­low­er ther­a­pies against vali­dat­ed drug tar­gets. [more in­for­ma­tion]
Medigene AG [MDG1:DB] €39 MM MCap
blue­bird bio col­lab; BLUE ini­ti­at­ing trial w/MDG MAGEA-4 can­di­date in 2020. TCRs tar­get­ing HA-1 & MAGE-A1 in de­vt. . DC vax in on­go­ing Ph 1/2; fi­nal read­out in 2019. [more in­for­ma­tion]
Monte Rosa Therapeutics [GLUE] $327 MM MCap
Mul­ti-as­set next-gen AI-driv­en molec­u­lar glue-based TPD plat­form. Lead pro­gram in Ph 1 fo­cused on GSP­T1, a key reg­u­la­tor and vul­n­er­a­bil­i­ty of MYC-driv­en solid tu­mors, in­clud­ing lung can­cer. [more in­for­ma­tion]
MorphoSys AG [MOR] $1,026 MM MCap
In its pro­pri­e­tary de­vel­op­ment seg­ment, the com­pany de­vel­ops anti­bodies that con­cen­trate on in­flam­ma­to­ry and au­toim­mune dis­eas­es, as well as can­cer and in­fec­tious dis­eas­es. [more in­for­ma­tion]
Nasdaq, Inc. [NDAQ] $28,185 MM MCap
Nas­daq's cor­po­rate ser­vices busi­ness (20%) of­fers list­ing ser­vices and re­lat­ed in­ves­tor re­la­tions prod­ucts to publi­c­ly trad­ed com­pa­nies. Through the com­pany's mar­ket tech­nol­o­gy group (15%), Nas­daq fa­cil­i­tates the exchange op­er­a­tions of other exchanges through­out the world and pro­vides fi­nan­cial com­pliance ser­vices. [more in­for­ma­tion]
Found­ed in 1724, Nau­ta­Du­tilh has grown to be­come one of the largest in the Benelux with over 400 lawy­ers, civ­il law no­taries and tax ad­vis­ers at of­fices in Am­s­ter­dam, Brus­sels, Lon­don, Lux­em­bourg, New York and Rot­ter­dam. What has kept Nau­ta­Du­tilh rel­e­vant all th­ese years is adap­tive think­ing. This sub­tle art is all about learn­ing how to think in­stead of be­ing taught what to think. [more in­for­ma­tion]
Nykode Therapeutics [NYKD]
Clin­i­cal stage im­munother­a­py com­pany fo­cused on can­cer and in­fec­tious dis­ease. Mo­d­u­lar vaccine tech­nol­o­gy tar­gets anti­gens to Anti­gen Pre­sent­ing Cells to achieve rapid, strong and long-last­ing im­mune re­spons­es. Key pro­grams in­clude Ph2 pro­pri­e­tary HPV 16+ cer­vi­cal can­cer ther­a­peu­tic vaccine, Ph1/2 in­di­vi­d­u­al­ized can­cer neoanti­gen vaccine (Ge­nen­tech). Sig­ni­f­i­cant col­lab­o­ra­tions with Re­generon and Ge­nen­tech. [more in­for­ma­tion]
Oryzon Genomics [ORY]
Tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A). Lead CNS com­pound in 3 Phase 2a trials in MS, AD and bas­ket trial. Onc com­pound in 2 com­bo Phase 2a trials in AML and SCLC. Da­ta exp mid-2019 [more in­for­ma­tion]
Phenex Pharmaceuticals AG
Phenex is a pri­vate­ly held drug dis­cov­ery and de­vel­op­ment com­pany head­quar­tered in Lud­wigshafen with a ma­jor re­search site in Hei­del­berg. The bio­phar­ma­ceu­ti­cal com­pany can built on four­teen years of ex­per­tise in ex­plor­ing and defin­ing in­no­va­tive, po­tent and se­lec­tive new drug can­di­dates from small molecules. Phenex ́ R&D ac­tiv­i­ties are cen­tered around dis­eas­es of the liv­er / gas­troin­testi­nal tract, as well as can­cer. [more in­for­ma­tion]
Prio­thera is de­vel­op­ing the oral­ly ap­plied sphin­go­sine 1 phos­phate (S1P) re­cep­tor mo­d­u­la­tors for hae­ma­to­log­i­cal ma­lig­nan­cies. [more in­for­ma­tion]
A phar­ma­ceu­ti­cal drug dis­cov­ery com­pany with pro­line de­rived mo­d­ules (ProMs) as the world’s first PRM struc­ture mim­ick­ing build­ing blocks. The com­pany de­vel­ops a new class of drugs and is able to ad­dress yet un­drug­gable con­sid­ered tar­gets that are re­lat­ed to vari­ous in­di­ca­tions. For its first of many use-cas­es, PRO­SION has al­ready shown a re­mark­able in vi­vo ef­fect of its ProM-based an­ti-me­tastat­ic in­hibi­tor – both in pan­cre­at­ic and breast can­cer xeno­graft ro­dent mod­els. [more in­for­ma­tion]
Silicon Valley Bank
The bank of­fers on­line and bank­ing ser­vices, pay­ments, de­posits and fraud pre­ven­tion ser­vices. In ad­di­tion, the com­pany of­fers in­vest­ments and as­set ma­n­age­ment ser­vices, cred­it so­lu­tions and com­mer­cial card pro­grams and strate­g­ic ad­vi­so­ry ser­vices, such as deal sourc­ing, bench­mark­ing, strate­g­ic val­u­a­tions and tran­s­ac­tion sup­port. Sil­i­con Val­ley Bank was found­ed in 1983 and is head­quar­tered in San­ta Clara, Cal­i­for­nia. [more in­for­ma­tion]
Solebury Strategic Communications
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. The firm’s glob­al reach ex­tends through a net­work of of­fices in New York, Bos­ton, San Fran­cis­co, Lon­don, Syd­ney and Shang­hai with con­tacts in all ma­jor fi­nan­cial cen­ters, help­ing clients to con­nect with the right in­ves­tors. [more in­for­ma­tion]
SOTIO a.s.
De­vel­op­er of Ac­tive Cel­lu­lar Im­munother­a­py (ACI) based on ac­ti­vat­ed den­drit­ic cells for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany op­er­ates as a biotech­nol­o­gy firm which de­vel­ops new ther­a­pies to ad­dress un­met med­i­cal needs us­ing its im­munother­a­py plat­form and pro­pri­e­tary cell-based tech­nolo­gies, en­abling state-of-the-art im­munother­a­py treat­ment for its pa­tients in Prague, Czech Re­public. [more in­for­ma­tion]
SphingoTec GmbH
Th­ese tests al­low for the di­ag­no­sis, out­come pre­dic­tion, and mon­i­tor­ing of acute med­i­cal con­di­tions, such as sep­tic shock, cir­cu­la­to­ry fail­ure, acute heart fail­ure and acute kid­ney in­jury. Sphin­goTec’s first-in-class tests are made avai­l­able on its pro­pri­e­tary whole-blood point-of-care Nexus IB10 plat­form for con­ve­nient and rapid test­ing in near-pa­tient and lab­o­ra­to­ry sett­ings along­side a broad port­fo­lio of stan­dard-of-care test for acute care. [more in­for­ma­tion]
sterna biologicals
KG is an in­no­va­tive clin­i­cal-stage im­munol­o­gy com­pany de­vel­op­ing nov­el treat­ments for chron­ic in­flam­ma­to­ry dis­eas­es such as asth­ma, chron­ic ob­struc­tive pul­mo­nary dis­ease (COPD), atopic der­mati­tis, and ul­cer­a­tive coli­tis. By tar­get­ing tran­scrip­tion fac­tors that play a cen­tral role in reg­u­lat­ing Th1- and Th2-driv­en in­flam­ma­to­ry mech­anisms, the Com­pany’s pro­pri­e­tary DNAzyme-based drug can­di­dates can in­ter­vene with up­stream in­flam­ma­to­ry pro­cess­es to ad­dress re­lat­ed dis­eas­es more ef­fec­tive­ly. Ster­na cur­rent­ly has four pro­grams in phase 2 de­vel­op­ment. [more in­for­ma­tion]
Targovax [TRVX]
Pre­lim­i­nary Ph1b da­ta of OV ON­COS-102+che­mo in me­sothe­lio­ma re­sults: com­bo mPFS=8.4 mos. vs. con­trol mPFS=6.8 mos.; 1L pts mPFS-8.9 mos. Up­com­ing mile­s­tones: up­dat­ed clin­i­cal & im­mune da­ta in Ph2 me­sothe­lio­ma (1H20); pre­clin­i­cal da­ta on next-gen OV w/ dou­ble trans­genes (1H20); and clin­i­cal da­ta from Ph1 me­lano­ma study, part 2 with ex­tend­ed dos­ing (2H20). [more in­for­ma­tion]
Tonix Pharmaceuticals [TNXP] $20 MM MCap
The com­pany is en­gaged in dis­cov­er­ing, li­cens­ing, ac­quir­ing and de­vel­op­ing drugs and bi­o­log­ics to treat and pre­vent hu­man dis­ease and alle­vi­ate suf­fer­ing. Its port­fo­lio in­cludes bi­o­log­ics to pre­vent in­fec­tious dis­eas­es and small molecules and bi­o­log­ics to treat pain, psychi­a­tric and ad­dic­tion con­di­tions. While the com­pany is al­so de­vel­op­ing a po­ten­tial vaccine to pro­tect against the nov­el coro­n­avirus dis­ease. [more in­for­ma­tion]
Vivoryon [VVY:AS] €360 MM MCap
De­vel­ops small molecule medicines that mo­d­u­late the ac­tiv­i­ty and sta­bil­i­ty of patho­log­i­cal­ly al­tered pro­teins. Lead can­di­date varog­lu­tam­s­tat, cur­rent­ly in VIVI­AD EU Ph2b and VI­VA-MIND US Ph2a/2b studies in Alzheimer’s dis­ease (AD), tar­gets all three ma­jor hall­marks of AD (Abe­ta pathol­o­gy, tau pathol­o­gy, neu­roin­flam­ma­tion) and sy­nap­tic im­pair­ment. [more in­for­ma­tion]
Wellington Partners
Found­ed in 1998, Welling­ton Part­n­ers is a ven­ture cap­i­tal firm based in Mu­nich, Ger­many. The firm seeks to in­vest in the ear­ly- and growth-stage tech­nol­o­gy and life sci­ence sec­tors. [more in­for­ma­tion]